

# UC Davis

## UC Davis Previously Published Works

### Title

Profiling of Differential Expression of Genes in Mice Carrying Both Mutant Presenilin 1 and Amyloid Precursor Protein Transgenes with or without Knockout of B2 Adrenergic Receptor Gene

### Permalink

<https://escholarship.org/uc/item/4pt4m1k5>

### Journal

Journal of Applied Bioinformatics & Computational Biology, 2018(03)

### ISSN

2329-9533

### Authors

Zhou, Yuan  
Chen, Lintao  
Zhou, Xi  
et al.

### Publication Date

2018

### DOI

10.4172/2329-9533.1000155

Peer reviewed



Published in final edited form as:

*J Appl Bioinforma Comput Biol*. 2018 ; 7(3): . doi:10.4172/2329-9533.1000155.

## Profiling of Differential Expression of Genes in Mice Carrying Both Mutant Presenilin 1 and Amyloid Precursor Protein Transgenes with or without Knockout of $\beta_2$ Adrenergic Receptor Gene

Yuan Zhou<sup>#1,2,3</sup>, Lintao Chen<sup>#1,4</sup>, Xi Zhou<sup>1,4</sup>, Yechun Pei<sup>1,4</sup>, Shuangshuang Wei<sup>1,4</sup>, Anum Mehmood<sup>1,4</sup>, Yang K Xiang<sup>2,5,\*</sup>, and Dayong Wang<sup>1,2,4,\*</sup>

<sup>1</sup>Laboratory of Biotechnology and Molecular Pharmacology, Hainan Key Laboratory of Sustainable Utilization of Tropical Bioresources, Hainan University, Haikou, Hainan 570208, China

<sup>2</sup>Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA

<sup>3</sup>Amber Glen Alzheimer's Association, 1704 Amber Ln, Urbana, IL 61802, USA

<sup>4</sup>College of Biology, Institute of Tropical Agriculture and Forestry, Hainan University, Haikou, Hainan 570208, China

<sup>5</sup>Department of Pharmacology, University of California, Davis, CA95616, USA

# These authors contributed equally to this work.

### Abstract

Alzheimer's disease (AD) is a lifelong progressive neurodegenerative disease related with accumulation of amyloid  $\beta$  peptide ( $A\beta$ ) produced by processing of amyloid precursor protein (APP) in the brain. In spite of several-decades effort on AD, there is still no medicine used to intervene with its pathological processes. Our previous studies made in transgenic animal models harboring familial AD genes of mutant presenilin 1 and amyloid precursor protein (APP) showed that  $\beta_2$ AR gene knock-out ( $\beta_2$ AR-KO) is beneficial in senile AD animals. Consistently, an epidemiological study lasted for two decades showed that the sole usage of  $\beta$  blockers as antihypertensive medicines is associated with fewer brain lesions and less brain shrinkage seen in senile AD patients. In order to understand why senile  $\beta_2$ AR-KO AD mice had better learning and memory, genomic effects of  $\beta_2$ AR-KO in the double transgenic AD mice were investigated. In the analysis, major genomic significance of  $\beta_2$ AR-KO was directed to influence protein-processing and presentation involving membrane structure and MHC class I and II protein complex, and lysosome and hydrolase activity for protein degradation, which are critical for accumulation of amyloid  $\beta$  peptide, the hallmark of AD.

\*Corresponding authors: Dayong Wang, Professor of Biochemistry and Molecular Biology, Laboratory of Biotechnology and Molecular Pharmacology, Hainan Key Laboratory of Sustainable Utilization of Tropical Resource, Hainan University, 817 Nong-Ke Lou, 58 People's Road, Meilan District, Haikou, Hainan 570208, China; Tel: +86-18789556728/+1-217-721-9757; wangdy@hainu.edu.cn, Yang K. Xiang, Department of Pharmacology, University of California, Davis, CA 95616, USA; Tel: 530-752-6895; ykxiang@ucdavis.edu.

## Keywords

$\beta_2$  adrenergic receptor; Alzheimer's disease; Genome; Differential expression; Protein processing and presentation; Lysosome

---

## Introduction

Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by accumulation of plaques composed of amyloid  $\beta$  peptides ( $A\beta$ ) in the brain related with abnormal processing and presentation of  $A\beta$  by cells [1]. Studies have shown that the number of  $\beta_2$  adrenergic receptor ( $\beta_2AR$ ) is increased in the prefrontal cortex and the hippocampus of AD subjects, while it is not correlated with age [2]. Since the cortex and the hippocampus are major brain regions that are highly degenerated in AD and the cortex is the earliest to form  $A\beta$  plaques, it is supposed that  $\beta_2AR$  may play an important role in AD [3]. A study has shown that chronic treatment with  $\beta_2AR$  agonist enhances  $\gamma$ -secretase activity, and related  $A\beta$  production and formation of  $A\beta$  plaques [4]. Using AD transgenic mouse model harboring human familial AD genes of mutant presenilin 1 (PS1) and amyloid precursor protein (APP), we have found that  $\beta_2AR$  gene knock-out (KO) improved learning and memory in 1-year-old senile AD mice, although there was a weak decreasing tendency of the performance in 6-month-old young wild type (WT) mice [5]. In addition, removing the gene encoding  $\beta_2AR$  increases the survival rate in P301S mutant tau-transgenic mice [6]. An epidemiological study showed that variations in  $\beta_2AR$  gene are involved in the pathogenesis of sporadic late onset Alzheimer's disease (LOAD) [2]. In an epidemiological study made in 2,197 participants conducted from 1991 to 2010, it was found that clinical use of  $\beta$ -blockers was associated with a lower risk of cognitive impairment, and the association was more obvious in senile men who were more than 75-years old [7]. An autopsy study made on 774 brains of male AD patients after death showed that the patients who took  $\beta$ -blockers had less brain lesions and shrinkage than those who took other medications for blood hypertension and those untreated, and their brains showed that they suffered less microinfarcts [8]. A parallel study showed that patients who took  $\beta$ -blockers experienced less cognitive decline as they aged compared to control groups [9].

$\beta_2AR$  which consists of seven transmembrane  $\alpha$ -helices belongs to G protein-coupled receptor superfamily and transduces signal via  $G\alpha_s$  and also  $G\beta\gamma$  proteins [10].  $\beta_2AR$  is distinct from  $\beta_1AR$  in that  $\beta_2AR$  internalizes after binding to isoproterenol or  $A\beta$  [11]. In response to  $\beta_2AR$  endogenous ligands norepinephrine and epinephrine,  $G\alpha_s$  dissociates from  $G\beta\gamma$  to stimulate adenylyl cyclase to produce cAMP, which activates protein kinase A (PKA) and the exchange protein activated by cAMP (Epac) [10,12].  $G\beta\gamma$  dimer interacts with many different proteins, and different combinations of  $G\beta$  and  $G\gamma$  subtypes transduce signals diversely with or without the association of  $G\alpha$  subunit to inhibit or activate various downstream signaling components, including ion channels, G protein-coupled receptor kinases (GRKs), phosphoinositide 3-kinase (PI3K), mitogen-activated protein kinases (MAPK) signaling mediated by small GTPase Ras, phospholipase A and C, and *etc* [13–16]. The signal transductions mediated by  $G\alpha_s$  and  $G\beta\gamma$  regulate a few of transcription factors, such as cAMP response element binding protein (CREB), extracellular signal-regulated

kinases (ERKs) and *etc.*, therefore,  $\beta_2$ AR activation regulates expression of genes, however integrative influence of  $\beta_2$ AR on genomic expression is still unknown.  $\beta_2$ ARs are expressed throughout the brain, abundantly in the cortex and the hippocampus, which are the two brain regions essential for higher cognitive functions [6]. Despite being involved in fundamental biological processes,  $\beta_2$ AR gene knockout (KO) mice are viable and fertile [6].

In the study, a genetic approach was adopted to remove  $\beta_2$ AR gene from a double transgenic mouse model of AD that overexpresses mutant human PS1 gene harboring M146L and L286V familial AD mutations, and APP gene (695) harboring Swedish (K670N, M671L), Florida (I716V) and London (V717I) mutations, and the effects of  $\beta_2$ AR-KO on genomic expression profiles in PS1/APP transgenic AD mice was investigated.

## Materials and Methods

### Animals

PS1/APP double transgenic and  $\beta_2$ AR-KO/PS1/APP mice in B6 background were described previously [11,17,18], and 1-year old mice were used for analysis of whole genome gene expression. The PS1/APP mice, which are transgenic animal models of Alzheimer's disease, were purchased from Jackson laboratory (stock number: 006554), which overexpress human PS1 gene harboring two familial AD mutations, M146L and L286V and APP (695) gene with Swedish (K670N, M671L), Florida (I716V) and London (V717I) familial AD mutations [18]. PS1/APP mice were crossbred with  $\beta_2$ AR-KO mice to produce  $\beta_2$ AR-KO/PS1/APP mice. All animal experimental procedures were approved by the Animal Care and Use Committee of University of Illinois and Hainan University.

### Whole-genome expression analysis

One-year-old PS1/APP and  $\beta_2$ AR-KO/PS1/APP mice were sacrificed, six mice in each group. The cerebrums were dissected out, and one side of the cerebral hemispheres of each mouse was used for the study. The cerebral hemispheres were homogenized separately on ice, and total RNA was extracted using RNeasy<sup>®</sup> Lipid Tissue Kit (Qiagen). Whole-genome expression profiles of PS1/ APP Alzheimer's disease mice and  $\beta_2$ AR-KO/PS1/APP mice were tested using the Mouse WG-6 v2.0 BeadChips and HiScan System (Illumina). The Mouse WG-6 v2.0 BeadChips have probes for the NCBI Mouse Reference Sequence (RefSeq) Release 22, including 26,766 manually annotated and reviewed coding transcripts designated as known mRNAs which begin with NM, 6,856 predicted coding transcripts (XM), and 56 annotation-well-established noncoding transcripts (XR). The BeadChips also have probes for 5,659 transcripts described in the Japan RIKEN Functional Annotation of Mouse (FANTOM) 24–6 database, 3,573 additional sequences listed in the RefSeq Release 5 (Build 33.1), and 2,371 sequences listed in the Mouse Exonic Evidence Based Oligonucleotide (MEEBO) set. In the single factor experimental design, PS1/APP transgenic mice were used as background controls for the gene expression profile of the Alzheimer's disease model, and  $\beta_2$ AR-KO was the only factor of treatment.

## Results

### Principal components analysis for all biological samples

Principal component analysis (PCA) is a multivariate statistical method to analyze internal correlation or variation among original variables by constructing linear combinations of the variables, which were gene expression levels in the study. During the process the dimensionality of original variables is reduced and the newly constructed variables designed to preserve much original information are independent to each other. The linear combination with biggest variance is treated as the first or the primary principal component (PC), which was designated as PC1 in the study, and the second one was PC2. The PCs which were orthogonal to each other effectively show variation of gene expression levels among thousands of noise in each subject. In the study, PC1 showed that  $\beta_2$ AR-KO-induced significant change in genomic expression, in that the two experimental groups which are PS1/APP double transgenic AD mice (PA) and  $\beta_2$ AR-KO/PS1/APP mice (B2P) were distributed in two separated regions along the PC1 axis; PC1s for PA samples fell into the region from 19 to 39, however, B2P samples were in the region from -40 to -12 (data not shown). In other words,  $\beta_2$ AR-KO in PS1/APP mice significantly changed the distribution of PC1 values, indicating a prominent consequence resulted from  $\beta_2$ AR-KO.

### Numeric statistics of differentially expressed genes (DEGs) related with $\beta_2$ AR-KO in transgenic animal model of AD

Raw data of the expression levels of the 45,281 transcripts were normalized to systematic differences between different BeadChips. Differential expression analysis on the normalized data was made by DEseq. Those genes whose normalized expression levels have absolute values of log2 ratio that are not less than one and a false discovery rate less than 0.05 ( $q < 0.05$ ) were taken as DEGs. Knock-out of  $\beta_2$ AR gene significantly changed the expression levels of more than 50% of total genes manifested as the total transcripts probed, with down-regulated transcripts being more than up-regulated transcripts (Figures 1a, 1b).

### Hierarchical cluster analysis of DEGs related with $\beta_2$ AR-KO in transgenic animal model of AD

Hierarchical cluster analysis is a statistical approach to assign normalized DEG values into different clusters, with intra-cluster difference being much smaller than intercluster difference. It is different from classification in that it is an unsupervised mathematical grouping regardless of biological functions related with a normalized value. Phenotype structures of the samples are revealed by a hierarchical clustering figure. The R software was used by us to show two-dimensional hierarchical clustering. One dimension of the construction is the biological samples listed individually in horizontal, the other is DEGs identified in the above statistics. A dendrogram along the vertical axis showing hierarchical clustering of DEGs was achieved according to the Euclidean metrics of the Log2 values of the expression levels of DEGs (Figure 2). Zooming in the hierarchical clustering diagram, the most intuitive changes are that the DEGs with moderate transcriptional levels in PS1/APP mice are obviously decreased by  $\beta_2$ AR-KO, and some other genes with relatively lower transcriptional levels are obviously increased.

### Gene ontology (GO) classification of DEGs related with $\beta_2$ AR-KO in transgenic animal model of AD

Currently, GO construction is aimed to pave the way to interpret or predict functions of genes or proteins by extracting and analyzing gene-related knowledges accumulated in large amount of literatures, leading to artificial intelligence. In GO consortium, there are three independent ontology domains, which are biological processes, cellular component and molecular function, using controlled vocabularies which are updated dynamically. In each of the three domains, there are subdomains to form tree structures with levels, nodes and relationships. According to the biological terms at the third level specified in the GO database typically, the expression of genes up- or down-regulated by  $\beta_2$ AR-KO are classified and counted (Figure 3). There are four biological processes that are prominently affected by  $\beta_2$ AR-KO, which are cellular process, single-organism process, metabolic process and biological regulation, each comprises more than 35% of total DEGs. In the domain of cellular components, gene expression levels that are mostly changed by  $\beta_2$ AR-KO are cell part, membrane, membrane part, organelle, organelle part and macromolecular complex. In the domain of molecular function, the most prominent result is that the genes whose biological function is relevant to binding comprises more than 50% of total DEGs. At this step, these results primarily associated  $\beta_2$ AR with membrane and its main function which is binding, which are indispensable for protein processing and presentation, which are immunological functions and shown in the following section.

### Q-value distribution of GO terms enriched with DEGs related with $\beta_2$ AR-KO in transgenic animal model of AD

In order to control increased probability of type I error within all rejections associated with multiple hypothesis test of differential expression levels, false discovery rate (FDR) was calculated. The q-value is the minimum positive FDR (pFDR) to reject a null hypothesis for a given rejection region  $\Gamma_\alpha$  of a GO term enriched with genes and an observed statistic  $T=t$ , and is defined as  $\inf_{\Gamma_{\{\alpha:t\}} \Gamma_\alpha} \text{pFDR}(Th)$  (19). The distribution charts for GO term-enriched DEGs related with  $\beta_2$ AR-KO were drawn according to q-values (Figures 4, 5a, 5b). The biological process (BP) domain comprises terms describing series of events accomplished by organized assemblies of molecular functions in living units. In GOBP, most of the terms enriched with DEGs are directly related with immunological function; there are 88 in total 117 terms are related, and 54 in 68 terms have very high strength which were highlighted in red (Figure 4). The top 3 highest enriched GO terms showed that  $\beta_2$ AR primarily affects protein processing and presentation in the transgenic animal model of AD, which is pertinent to abnormal A $\beta$  accumulation in the brain (Figure 4). Besides the top 3, twelve terms showed facets of the protein processing and presentation affected by  $\beta_2$ AR-KO, including MHC class I and II mediating presentation of endogenous and exogenous proteins, peptides and even polysaccharides (Figure 4). In addition to the primary effects of  $\beta_2$ AR on gene expression, other genes are also affected. There are six enriched GO terms related with protein folding, four related with nitric oxide synthesis, three related with response to stimulus, and ten related with chemical metabolism (Figure 4). Another two terms drawn attention are mRNA splice site selection and sphingolipid biosynthesis (Figure 4). In the GO domain of cellular component (CC), almost all of the terms are membrane-related events (27 out of total 30 terms), including MHC protein complex, plasma membrane, external side of

plasma membrane, intrinsic component of membrane, endosome, vesicle, secretory granule and *etc.* (Figure 5a). The most prominent GOCC results are consistent with GOBP (Figure 5a). In the GO domain of molecular function, there are only two significantly enriched terms, and the most affected one is unfolded protein binding, which is a membrane function related with protein processing and presentation (Figure 5b).

### Hierarchical relationships of GO terms highly enriched with DEGs related with $\beta_2$ AR-KO in transgenic animal model of AD

Hierarchical relationships among GO terms highly enriched with DEGs were shown by directed acyclic graphs (DAG) in detail (Figures 6–8). DAG was drawn based on automated analysis in each of the three independent GO ontologies which are biological process, cellular component and molecular function. In each of the three GO ontologies, top five DEGs-enriched GO terms are major nodes in DAG. In GOBP, all six highly enriched nodes are related to immune, with q-values ranging from  $3.05 \times 10^{-14}$  to  $1.57 \times 10^{-9}$ , and 4 out of the 6 nodes showed that  $\beta_2$ AR-KO fundamentally changed expression levels of genes regulating antigen processing (Figure 6). Top genes annotated in GO to be related to antigen processing and presentation were listed in the sequence of the fold of change (Table 1). In GOCC, the GO terms enriched with DEGs whose expression was affected by  $\beta_2$ AR-KO are directed toward two directions. One group of GOCC nodes are directed toward MHC protein complex which was highly enriched with a q value of  $1.3 \times 10^{-9}$  through 3 paths, two of which are significantly enriched and related with membrane (Figure 7). The other group of GOCC nodes are directed toward a one-way path consisted of three consecutive nodes starting from vacuole ( $q=1.93 \times 10^{-10}$ ), which in animals are typically founded in the protein-processing steps of endocytosis and exocytosis, and ending with lysosome ( $q=6.32 \times 10^{-11}$ ) which is a component of protein processing and presentation (Figure 7). Top genes annotated in GO to be related to lysosome (Tables 2a and 2b) and MHC protein complex (Tables 3a and 3b) were listed in the sequence of the fold of change. In GOMF, there are 3 unrelated paths. One is the hydrolase activity path, which can be found in lysosomes and related to protein processing and presentation. The hierarchical node sequence in the hydrolase activity path is catalytic activity (GO:0003824,  $q=7.064 \times 10^{-3}$ , enrichment rate (ER):1181/6588), hydrolase activity (GO:0016787,  $q=2.29 \times 10^{-4}$ , ER: 521/2686), hydrolase activity acting on glycosyl bonds (GO:0016798,  $q=3.23 \times 10^{-4}$ , ER: 37/125) and hydrolase activity hydrolyzing O-glycosyl compounds (GO: 0004553,  $q=2.11 \times 10^{-5}$ , ER: 34/99) (Figure 8). Top genes annotated in GO to be related to hydrolase activity were listed in the sequence of the fold of change (Tables 4a and 4b). Another path is directed toward unfolded protein binding, which is a step of protein processing and presentation and may be related with AD pathology. The node sequence of the binding path is binding (GO: 0005488,  $q=2.0986 \times 10^{-2}$ , ER: 2376/13682), protein binding (GO: 0005515,  $q=4.253 \times 10^{-3}$ , ER: 1383/7736) and unfolded protein binding (GO: 0051082,  $q=2.05 \times 10^{-5}$ , ER: 36/107) (Figure 8). Top genes annotated in GO to be related to unfolded protein binding were listed in the sequence of the fold of change (Table 5). The third path is from the node of enzyme regulatory activity (GO: 0030234,  $q=1.6829 \times 10^{-2}$ , ER: 175/889), which is reserved for cases when the regulator directly interacts with the enzyme, to nitric-oxide synthase regulator activity (GO: 0030235,  $q=1.41 \times 10^{-4}$ , ER: 5/5) (Figure 8). Besides, by further reviewing of DEG data, it was found that the expression of all 5 genes comprised in GO nodes of nitric-oxide synthase

regulator activity was decreased by  $\beta_2$ AR-KO in the transgenic AD animal model. In addition to the above GO analysis, the genes that are annotated to be related to AD in the KEGG's pathways were listed in Table 6, including Apolipoprotein E, which is the strongest genetic risk factor for both early- and late-onset AD found in one third of the cases of AD.

## Discussion

AD has baffled scientists ever since German psychiatrist Alois Alzheimer reported the first case of AD in 1906, the cause of which has been poorly understood until now [19,20], and there is neither treatment to intervene its development, nor particular measure to be effective in preventing or delaying the onset of AD [21].

Traditional amyloid hypothesis proposes that abnormal accumulation and aggregation of A $\beta$  in the brain is the central event triggering neuronal degeneration in AD, which may be related to abnormal protein processing and presentation. Since the early days, the aggregated A $\beta$  has been believed to be the causal factor of AD disrupting homeostasis of calcium ions in neurons and inducing apoptosis [22,23]. However, the driving force for abnormally increased accumulation and aggregation of A $\beta$  in AD are still vague. In recent years, psychological stress has been identified to be a possible trigger for AD, and the roles of adrenergic receptors especially  $\beta_2$ AR have attracted researchers' notice. Partially because of the inconsistency in the localization of aggregated A $\beta$  plaques and degenerated neurons, in recent years, the effects of soluble A $\beta$  including A $\beta$  dimers have been studied [5,17,24–26]. In recent studies on soluble A $\beta$ , the role of  $\beta_2$ AR in mediating some of the effects of soluble A $\beta$  has been identified [5,6,17,26]. It has been found that polymorphism of  $\beta_2$ AR gene may play a role in the pathogenesis of sporadic late - onset Alzheimer's disease (LOAD) in that both the 16Gly allele and the 27Glu allele of the  $\beta_2$ AR gene were associated with an increased risk of LOAD and there was a significant interaction with the apolipoprotein E gene  $\epsilon 4$  allele, the presence of which markedly increases the incidence of LOAD (3). From a point of view, a study showed that activation of  $\beta_2$ AR enhances  $\gamma$ -secretase activity and A $\beta$  production, which requires agonist-induced internalization of both  $\beta_2$ AR and PS1 in a complex to late endosomes and lysosomes, where A $\beta$  production was increased [4]. Furthermore, cerebral amyloid plaques were increased by chronic treatment with  $\beta_2$ AR agonists in animal model of AD [4]. A genetic study showed a complicated scenario:  $\beta$ AR may be related to AD through numerous factors, including human leukocyte antigen genes, the renin-angiotensin system, poly (adenosine diphosphate- ribose) polymerase 1, nerve growth factor, vascular endothelial growth factor, the reduced form of nicotinamide adenine dinucleotide phosphate, matrix metalloproteinases, mitogen-activated protein kinase pathways, prostaglandins, cyclooxygenase-2, and nitric oxide synthase [27]. In AD patients, there is the loss of neurons in the locus ceruleus (LC), however the density of  $\beta_2$ AR is increased in the cortical laminae II, III, IV and V in AD patients [2], whereas the cortex is highly degenerated during the development of AD, and is the earliest region to have A $\beta$  deposition [28]. The observed results indicated the association of  $\beta_2$ AR with AD.

Major discoveries in the study first arose from the analysis of q-value distribution of GO terms enriched with DEGs that are related with  $\beta_2$ AR-KO in the three GO domains, which are GOBP, GOCC and GOMF. The q-value introduced by John D. Storey in 2003 is a



measure of the probability of type I error within all statistical rejections made for the test of differential expression of genes, instead of within all samples, and it is a multiple hypothesis testing quantity and a natural counterpart to the p-value [19,29]. The q-value is the minimum pFDR to reject the null hypothesis that  $\beta_2$ AR-KO induces no change for a specified rejection region and an observed statistic [19,29]. FDR was calculated to control the probability of type I error which was increased when multiple hypothesis tests are applied to massive samples of DNA microarray. In the study, the q-values are indicated with each statistic when multiple hypothesis tests were made using FDR [19,29]. The q-value distribution analysis revealed major effects of  $\beta_2$ AR-KO in the transgenic animal model of AD. In the first place, in GOBP most of the DEGs affected by  $\beta_2$ AR-KO are related to immunological processes, in which the top 3 GO terms are antigen processing and presentation of peptide antigen, antigen processing and presentation, and antigen processing and presentation of endogenous peptide antigen. In GOCC, the notion was supported by that most of the terms are related to membrane structure and function, especially the MHC I and II protein complexes which are essential elements for endogenous and exogenous protein processing and presentation. In GOMF, the only two significantly enriched entries strengthened the above notion; one is unfolded protein binding, the other is hydrolase activity hydrolyzing O-glycosyl compounds. The GO synonym of binding is involved in both the posttranslational folding process aided by chaperones to form correct three-dimensional conformation and tagging of proteins for degradation. Some of misfolded proteins are degraded in cytosol. Aberrant folding processes and accumulation of misfolded proteins may be related with neurodegeneration including AD. The q-value distribution analysis in the three GO domains was the first step to show consistently that the immunological effects of  $\beta_2$ AR-KO on protein processing and presentation for both endogenous and exogenous proteins.

DAGs showed in detail the hierarchical relationships of GO terms that were enriched with DEGs affected by  $\beta_2$ AR-KO in the transgenic animal model of AD. In the three GO domains, which are GOBP, GOCC and GOMF, the hierarchical relationships were shown by networks connecting GO nodes, in each of which the genes are assorted using an updated and controlled GO vocabulary. In the domains, the effects of  $\beta_2$ AR-KO on the expression of genes for protein processing and presentation was further interpreted showing the relationship between the genomic effects of  $\beta_2$ AR-KO on membrane structures, hydrolysis of proteins in lysosome, presentation of processed protein debris through MHC protein complex. In GOBP,  $\beta_2$ AR-KO affected not only immune response but also antigen processing and presentation. On one hand, the immune response was affected through both the response to stimulus and immune system process involved in the development and functioning of the immune system. The two aspects have been thought to be factors influencing the onset of AD. On the other hand, the four interconnected GO nodes showed that fundamental effects of  $\beta_2$ AR-KO on genomic expression were to change antigen processing and presentation including proteins, peptides and lipids. In GOCC, the genomic effects of  $\beta_2$ AR-KO on lysosome and MHC protein complex were revealed, which are cellular components required for protein processing and presentation. In addition to exogenous antigens, intracellular peptides can be presented to TCRs as potential foreign antigens by complexing with MHCs. MHC molecule and the processed antigen bound to it interact with both CD4/CD8 coreceptors and variable Ig-like domain of TCR on cell surface

to trigger activation of T lymphocytes [30]. Proteins or peptides are processed and presented by two classical pathways: cytosolic MHC class I and endocytic MHC class II pathways. In cytosolic or endogenous pathway, any nucleated cell presents cytosolic proteins by MHC class I molecules, including not only endogenous peptides derived from defective translation or protein turn over but also heterogenous proteins resulted from microorganism infection or cancerous proteins degraded by proteasome. Upon recognizing MHC I molecules, natural killer (NK) cells are inhibited, therefore NK cells recognize stressed cells to induce apoptosis faster when there is a reduction of MHC class I molecules on the surface of stressed cells. In endocytic or exogenous pathway, antigen-presenting cells, such as dendritic cells and macrophages phagocytize antigens into phagosomes. After they matured to lysosomes, antigens are cleaved and processed by acidic hydrolases, then bind to MHC class II molecules on cell surface. The cleaved peptides bound to MHC molecules on lysosomal membrane and exhibiting immunodominance are trafficked to and externalized on cell surface for presentation [31]. In addition to the major genomic effects of  $\beta_2$ AR on protein processing and presentation, in GOMF, there are three subfields directed to unfolded protein binding, hydrolase activity hydrolyzing O-glycosyl compounds and nitric-oxide synthase regulator activity. The synonyms of unfolded protein binding comprise chaperone activities, including fimbrium-specific, glycoprotein-specific, histone-specific, ribosomal and tubulin-specific activities, and binding unfolded endoplasmic reticulum proteins. The parent term for “unfolded protein binding” is protein binding, the synonyms of which are protein amino acid binding, protein degradation tagging activity, protein tagging activity, protein folding chaperone and alpha-2 macroglobulin receptor-associated protein activity.

## Conclusion

The analyzation in the transgenic animal models of AD showed genomic effects of  $\beta_2$ AR-KO on immunological processes, which are mainly protein-processing and presentation activities involving membrane structure and MHC class I and II protein complex. Besides, protein folding and degradation participated by chaperones and misfolded protein tagging are also affected by  $\beta_2$ AR-KO.

## Acknowledgments


We thank Branden Skarpiak and Elaine Wu for assistance in genotyping of laboratory mice. This work was supported by a Natural Science Foundation of Hainan Province 314058 (D.W.), a National Institute of Heart, Blood, and Lung grant HL082846 (Y.K.X.), and grants from National Natural Science Foundation of China 31460226 (D.W.) and 31760246 (D.W.). D.W. is a recipient of a NARSAD award and an Illinois Department of Public Health grant.

## References


1. Murphy MP, LeVine H (2010) Alzheimer's disease and the Amyloid- $\beta$  Peptide. *J Alzheimers Dis* 19: 311–323. [PubMed: 20061647]
2. Kalaria RN, Andorn AC, Tabaton M, Whitehouse PJ, Harik SI, et al. (1989) Adrenergic receptors in aging and Alzheimer's disease: Increased  $\beta_2$ -Receptors in prefrontal cortex and hippocampus. *J Neurochem* 53: 1772–1781. [PubMed: 2553864]
3. Yu JT, Tan L, Ou JR, Zhu JX, Liu K, et al. (2008) Polymorphisms at the beta2-adrenergic receptor gene influence Alzheimer's disease susceptibility. *Brain Res* 1210: 216–222. [PubMed: 18423577]

4. Ni Y, Zhao X, Bao G, Zou L, Teng L, et al. (2006) Activation of beta2-adrenergic receptor stimulates gamma-secretase activity and accelerates amyloid plaque formation. *Nat Med* 12: 1390–1396. [PubMed: 17115048]
5. Wang D, Fu Q, Zhou Y, Xu B, Shi Q, et al. (2013)  $\beta$ 2 adrenergic receptor, protein kinase A (PKA) and c-Jun N-terminal kinase (JNK) signaling pathways mediate tau pathology in Alzheimer disease models. *J Biol Chem* 288: 10298–10307. [PubMed: 23430246]
6. Wisely EV, Xiang YK, Oddo S3 (2014) Genetic suppression of  $\beta$ 2-adrenergic receptors ameliorates tau pathology in a mouse model of tauopathies. *Hum Mol Genet* 23: 4024–4034. [PubMed: 24626633]
7. Gelber RP, Ross GW, Petrovitch H, Masaki KH, Launer LJ, et al. (2013) Antihypertensive medication use and risk of cognitive impairment: The Honolulu-Asia Aging Study. *Neurol* 81: 888–895.
8. White LR, Gelber RP, Launer LJ, Zarow C, Sonnen J, et al. (2013) Three-dimensional study of neuromuscular junctions (NMJ) in heterozygous R98C knock-in CMT1B mouse model by overexpression Neuregulin 1 Type III. *Neurol* 80: S44.005.
9. Gelber RP, Ross GW, Petrovitch H, Masaki KH, Launer LJ, et al. (2013) Antihypertensive medication use and risk of cognitive impairment: The Honolulu-Asia aging study. *Neurol* 81: 888–895.
10. Dupre DJ, Herbert TE, Jockers R (2012) GPCR signalling complexes: Synthesis, assembly, trafficking and specificity. Springer Netherlands.
11. Wang D, Yuen EY, Zhou Y, Yan Z, Xiang YK (2011) Amyloid beta peptide-(1–42) induces internalization and degradation of  $\beta$ 2 adrenergic receptors in prefrontal cortical neurons. *J Biol Chem* 286: 31852–31863. [PubMed: 21757762]
12. Gloerich M, Bos JL (2010) Epac: Defining a new mechanism for cAMP action. *Annu Rev Pharmacol Toxicol* 50: 355–375. [PubMed: 20055708]
13. Clapham DE, Neer EJ (1997) G protein beta gamma subunits. *Annu Rev Pharmacol Toxicol* 37: 167–203. [PubMed: 9131251]
14. Wickman KD, Iniguez-Lluhl JA, Davenport PA, Taussig R, Krapivinsky GB, et al. (1994) Recombinant G-protein  $\beta\gamma$ -subunits activate the muscarinic-gated atrial potassium channel. *Nature* 368: 255–257. [PubMed: 8145826]
15. Kim D, Lewis DL, Graziadei L, Neer EJ, Bar-Sagi D, et al. (1989) G-protein beta Gamma-subunits activate the cardiac muscarinic K<sup>+</sup>-channel via phospholipase A2. *Nature* 337: 557–560. [PubMed: 2492640]
16. Khan SM, Sleno R, Gora S, Zylbergold P, Laverdure JP, et al. (2013) The expanding roles of G $\beta\gamma$  subunits in G Protein-coupled receptor signaling and drug action. *Pharmacol Rev* 65: 545–577. [PubMed: 23406670]
17. Wang D, Govindaiah G, Liu R, De Arcangelis V, Cox CL, et al. (2010) Binding of amyloid  $\beta$  peptide to  $\beta$ 2 adrenergic receptor induces PKA-dependent AMPA receptor hyperactivity. *FASEB J* 24: 3511–3521. [PubMed: 20395454]
18. Oakley H, Cole SL, Logan S, Maus E, Shao P, et al. (2006) Intraneuronal  $\beta$ -Amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: Potential factors in amyloid plaque formation. *J Neurosci* 26: 10129–10140. [PubMed: 17021169]
19. Storey JD, Tibshirani R (2003) Statistical methods for identifying differentially expressed genes in DNA microarrays. *Methods Mol Biol* 224: 149–157. [PubMed: 12710672]
20. Burns A, Iliffe S (2009) Alzheimer's disease. *BMJ* 338: b158. [PubMed: 19196745]
21. Kawas CH (2006) Medications and diet: Protective factors for AD? *Alzheimer Dis Assoc Disord* 20: S89–96. [PubMed: 16917203]
22. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, et al. (2011) Alzheimer's disease. *Lancet* 377: 1019–1031. [PubMed: 21371747]
23. Yankner BA, Duffy LK, Kirschner DA (1990) Neurotrophic and neurotoxic effects of amyloid beta protein: Reversal by tachykinin neuropeptides. *Science* 250: 279–282. [PubMed: 2218531]
24. Lesne SE, Sherman MA, Grant M, Kuskowski M, Schneider JA, et al. (2013) Brain amyloid- $\beta$  oligomers in ageing and Alzheimer's disease. *Brain* 136: 1383–1398. [PubMed: 23576130]


25. Mc Donald JM, Savva GM, Brayne C, Welzel AT, Forster G, et al. (2010) The presence of sodium dodecyl sulphate-stable A $\beta$  dimers is strongly associated with Alzheimer-type dementia. *Brain* 133: 1328–1341. [PubMed: 20403962]
26. Wang D, Xiang YK (2011)  $\beta$ -adrenergic receptor, amyloid  $\beta$ -peptide, and Alzheimer's disease. *Curr Top Membr* 67: 205–228. [PubMed: 21771492]
27. Luong K, Nguyen LT (2013) The role of beta-adrenergic receptor blockers in Alzheimer's disease. *Am J Alzheimers Dis Other Demen* 28: 427–439. [PubMed: 23689075]
28. Ross JA, McGonigle P1, Van Bockstaele EJ (2015) Locus Coeruleus, norepinephrine and A $\beta$  peptides in Alzheimer's disease. *Neurobiol Stress* 2: 73–84. [PubMed: 26618188]
29. Storey JD, Tibshirani R (2003) Statistical significance for genomewide studies. *Proc Natl Acad Sci U S A* 100: 9440–9445. [PubMed: 12883005]
30. Münz C (2016) Autophagy beyond intracellular MHC Class II antigen presentation. *Trends Immunol* 37: 755–763. [PubMed: 27667710]
31. Aderem A, Underhill DM (1999) Mechanisms of phagocytosis in macrophages. *Annu Rev Immunol* 17: 593–623. [PubMed: 10358769]



**Figure 1:** Numeric statistics of differentially expressed genes whose expression was affected by  $\beta_2$ AR-KO. a. Count of differentially expressed genes. The statistical analysis was made with DEseq. The criteria for differentially expressed genes were defined as  $|\log_2\text{Ratio}| \geq 1$  and  $q < 0.05$ , where Ratio equals to fold change. b. Volcano plot showing expression levels of genes affected by  $\beta_2$ AR-KO. PA, PS1/APP double transgenic mice. B2P,  $\beta_2$ AR-KO PS1/APP-double transgenic mice.



**Figure 2:** Hierarchical clustering analysis for differentially expressed genes. The dendrogram on the left shows the hierarchical clustering of the genes which was made according to the Euclidean distance of Log<sub>2</sub> values of the expression levels of the genes. The red color indicates relatively high levels of genes expression, and the blue color indicates relatively low gene expression levels. PA, PS1/APP double transgenic mice. B2P,  $\beta_2$ AR-KO PS1/APP double transgenic mice.




**Figure 3:** GO classification of differentially expressed genes. Up- and down-regulated genes are assorted under GO terms in the three GO domains, which are biological process, cellular component and molecular function. PA, PS1/APP double transgenic mice. B2P,  $\beta_2$ AP-KO PSI/APP-double transgenic mice.




**Figure 4:** Q-value distribution of GO terms enriched with differentially expressed genes in GO domain of biological process. Statistical significance is denoted by shades of color; a smaller q-value is signified by a darker color, and vice versa. PA, PS1/APP double transgenic mice. B2P,  $\beta_2$ AP-KO PS1/APP-double transgenic mice.







**Figure 5:** Q-value distribution of GO terms enriched with differentially expressed genes in GO domains of cellular component and molecular function. Statistical significance is denoted by shades of color; a smaller q-value is signified by a darker color, and vice versa. PA, PS1/APP double transgenic mice. B2P,  $\beta$ 2AR-KO PS1/APP-double transgenic mice.



**Figure 6:** DAG showing hierarchical relationships of GO terms highly enriched with differentially expressed genes in GO domain of biological process. Five top-enriched GO terms denoted with rectangles are major nodes of the DAG, and relationships of interrelated GO terms were shown in the diagram. Each node in the DAG was shown with a unique GO access number, title, q-value and the proportion of enriched genes in the node. Statistical significance is denoted by shades of color; a smaller q-value is signified by a darker color, and vice versa.



**Figure 7:** DAG showing hierarchical relationships of GO terms highly enriched with differentially expressed genes in GO domain of cellular component. Five top-enriched GO terms denoted with rectangles are major nodes of the DAG, and relationships of interrelated GO terms were shown in the diagram. Each node in the DAG was shown with a unique GO access number, title, q-value and the proportion of enriched genes in the node. Statistical significance is denoted by shades of color; a smaller q-value is signified by a darker color, and vice versa.



**Figure 8:** DAG showing hierarchical relationships of GO terms highly enriched with differentially expressed genes in GO domain of molecular function. Five top-enriched GO terms denoted with rectangles are major nodes of the DAG, and relationships of interrelated GO terms were shown in the diagram. Each node in the DAG was shown with a unique GO access number, title, q-value and the proportion of enriched genes in the node. Statistical significance is denoted by shades of color; a smaller q-value is signified by a darker color, and vice versa.

Profiles of differentially expressed genes in  $\beta_2$ AR-KO transgenic AD model annotated to be related to antigen processing and presentation in Gene Ontology.

**Table 1:**

Items	Gene ID	Fold Chg.	p Value	q Value
Histocompatibility 2, class II antigen A, beta 1	14961	8.871354	1.91E-06	0.000375
CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated)	16149	6.778798	2.57E-05	0.002088
Cathepsin E	13034	5.167045	2.08E-07	9.51E-05
Histocompatibility 2, D region locus 1	14964	3.86412	6.03E-07	0.000192
Histocompatibility 2, K1, K region	14972	3.259361	3.27E-05	0.002469
Proteasome (prosome, macropain) subunit, beta type 9 (large multifunctional peptidase 2)	16912	2.908455	3.20E-05	0.00244
Histocompatibility 2, class II, locus Mb1	14999	2.430133	5.14E-07	0.000173
Histocompatibility 2, class II, locus Mb2	15000	2.132515	3.91E-08	2.70E-05
Solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1	18173	2.006802	1.74E-05	0.001625
Histocompatibility 2, O region alpha locus	15001	1.993441	0.000614	0.01491
Proteasome (prosome, macropain) subunit, beta type 9 (large multifunctional peptidase 2)	16913	1.861686	0.000539	0.013966
Fe receptor, IgE, high affinity I, gamma polypeptide	14127	1.769161	8.53E-05	0.004534
Beta-2 microglobulin	12010	1.684328	4.52E-05	0.003045
Transporter 2, ATP-binding cassette, sub-family B (MDR/TAP)	21355	1.628326	0.003592	0.042868
Fe receptor, IgG, low affinity Iib	14130	1.62805	0.000151	0.006517
Histocompatibility 2, M region locus 3	14991	1.626856	1.77E-05	0.001647
Unc-93 homolog B1 (C. elegans)	54445	1.538428	0.000216	0.00799
Nucleotide-binding oligomerization domain containing 1	107607	1.503754	0.000728	0.016624
Fe receptor, IgG, low affinity III	14131	1.411944	0.001029	0.021051
Fe receptor, IgG, alpha chain transporter	14132	1.33175	0.003783	0.044161

Profiles of differentially expressed genes in  $\beta_2$ AR-KO transgenic AD model annotated to be related lysozyme in Gene Ontology (Part D).

**Table 2a:**

Items	Gene ID	Fold Chg.	p Value	q Value
CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated)	16149	6.778798	2.57E-05	0.002088
Cathepsin C	13032	5.514072	0.002342	0.033643
Interleukin 4 induced 1	100328588	2.760841	0.000134	0.006
Solute carrier family 15, member 3	65221	2.480609	1.68E-07	8.88E-05
CD68 antigen	12514	2.203099	6.29E-06	0.000837
Heparanase	15442	2.188486	6.48E-07	0.000198
RIKEN cDNA 5430435G22 gene	226421	2.148704	4.72E-05	0.003128
Histocompatibility 2, class II, locus Mb2	15000	2.132515	3.91E-08	2.70E-05
Alpha-N-acetylglucosaminidase (Sanfilippo disease IIIB)	27419	2.13038	6.49E-06	0.000851
Solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1	18173	2.006802	1.74E-05	0.001625
Prolylcarboxypeptidase (angiotensinase C)	72461	1.972664	5.00E-05	0.003226
N-sulfoglucosamine sulfohydrolase (sulfamidase)	27029	1.965037	1.81E-05	0.001656
Glucuronidase, beta	110006	1.954243	1.93E-05	0.001715
Cathepsin Z	64138	1.944783	4.78E-05	0.003156
Lysosomal-associated protein transmembrane 5	16792	1.943501	2.60E-06	0.000457
Mannosidase 2, alpha B1	17159	1.755669	6.14E-05	0.003691
Arylsulfatase G	74008	1.669844	0.00139	0.024861
LPS-induced TN factor	56722	1.644251	1.01E-05	0.001124
Lysosomal-associated membrane protein 2	16784	1.628241	2.08E-06	0.000394
Niemann Pick type C1	18145	1.623278	6.90E-06	0.000884
CD63 antigen	12512	1.619914	0.000166	0.006884
Ceroid lipofuscinosis, neuronal 3, juvenile (Batten, Spielmeier-Vogt disease)	12752	1.617276	5.01E-05	0.003226
Galactosidase, beta 1	12091	1.616097	3.79E-05	0.00271
Niemann Pick type C2	67963	1.614508	7.80E-06	0.00094
Deoxyribonuclease II alpha	13423	1.595048	0.00179	0.029031
Unc-93 homolog B1 (C. elegans)	54445	1.538428	0.000216	0.00799

Profiles of differentially expressed genes in  $\beta_2$ AR-KO transgenic AD model annotated to be related to lysozyme in Gene Ontology (Part II).

**Table 2b:**

Items	Gene ID	Fold Chg.	p Value	q Value
Cathepsin K	13038	7.580496	0.000158	0.006652
Cathepsin S	13040	10.41212	0.001679	0.027926
Sialidase 4	241159	5.623464	0.002891	0.037488
Peroxioredoxin 6	11758	5.989792	0.002557	0.035172
Syntaxin 8	55943	7.56421	0.001079	0.021551
Neuraminidase 1	18010	10.8563	0.000602	0.014729
Solute carrier family 29 (nucleoside transporters), member 3	71279	8.107022	0.003121	0.039352
RIKEN cDNA 061003.1106 gene	56700	9.661221	0.000288	0.009493
Iduronidase, alpha-L-	15932	7.167215	0.003211	0.039979
Immunity-related GTPase family M member 1	15944	7.71878	0.003203	0.039973
ATP-binding cassette, sub-family B (MDR/TAP), member 9	56325	9.114246	0.001726	0.028518
Corticotropin releasing hormone binding protein	12919	11.26217	0.000188	0.007354
Glucosidase, alpha, acid	14387	11.3279	0.00054	0.013971
Glucosidase, beta, acid	14466	9.797483	0.002908	0.037603
Phospholipase A2, group XV	192654	10.78939	0.002593	0.035401
Mannosidase, beta A, lysosomal	110173	8.529202	0.000965	0.020127
Ceroid-lipofuscinosis, neuronal 5	211286	9.777018	0.001512	0.026133
Vacuolar protein sorting 11 (yeast)	71732	9.435465	0.000712	0.016323
Lysosomal-associated membrane protein 1	16783	12.1733	0.001168	0.022445
Arylsulfatase B	11881	11.80603	0.002461	0.034612
VMA21 vacuolar H <sup>+</sup> -ATPase homolog (S. cerevisiae)	67048	10.57272	0.003456	0.041699
Transmembrane protein 55A	72519	11.26718	0.002119	0.031692
Sphingosine kinase 2	56632	4.96189	0.000586	0.014558
Iduronate 2-sulfatase	15931	6.259901	0.00208	0.031336
Transmembrane protein 74	239408	5.943605	2.08E-06	0.000394

Profiles of differentially expressed genes in  $\beta 2AR$ -KO transgenic AD model annotated to be related to MHC protein complex in Gene Ontology (Part D).

**Table 3a:**

Items	Gene ID	Fold Chg.	p Value	q Value
Histocompatibility 2, class II antigen A, beta 1	14961	8.871354	1.91E-06	0.000375
CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated)	16149	6.436063	9.77E-06	0.001104
cathepsin E	13034	5.167045	2.08E-07	9.51E-05
Histocompatibility 2, D region locus 1	14964	3.86412	6.03E-07	0.000192
Histocompatibility 2, Q region locus 8	15019	3.623889	1.40E-05	0.001408
Histocompatibility 2, K1, K region	14972	3.259361	3.27E-05	0.002469
Predicted gene 8909	667977	3.114538	8.43E-07	0.000229
Proteasome (prosome, macropain) subunit, beta type 9 (large multifunctional peptidase 2)	16912	2.908455	3.20E-05	0.00244
Histocompatibility 2, class II, locus Mb1	14999	2.430133	5.14E-07	0.000173
Eukaryotic translation initiation factor 2-alpha kinase 2	19106	2.220892	4.71E-07	0.00016
Histocompatibility 2, class II, locus Mb2	15000	2.132515	3.91E-08	2.70E-05
Lymphocyte-activation gene 3	16768	2.047944	0.000108	0.005212
Solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1	18173	2.006802	1.74E-05	0.001625
Histocompatibility 2, O region alpha locus	15001	1.993441	0.000614	0.01491
Proteasome (prosome, macropain) subunit, beta type 8 (large multifunctional peptidase 7)	16913	1.861686	0.000539	0.013966
Fe receptor, IgE, high affinity I, gamma polypeptide	14127	1.769161	8.53E-05	0.004534
Histocompatibility 2, K1, K region	14972	1.763206	2.74E-06	0.000472
DnaJ (Hsp40) homolog, subfamily C, member 16	214063	1.713747	1.49E-05	0.001453
beta-2 microglobulin	12010	1.684328	4.52E-05	0.003045
Transporter 2, ATP-binding cassette, sub-family B (MDR/TAP)	21355	1.628326	0.003592	0.042868
Fe receptor, IgG, low affinity Iib	14130	1.62805	0.000151	0.006517
Histocompatibility 2, M region locus 3	14991	1.626856	1.77E-05	0.001647
Protein tyrosine phosphatase, non-receptor type 6	15170	1.62081	0.000859	0.018684
Unc-93 homolog B1 (C. elegans)	54445	1.538428	0.000216	0.00799
Nucleotide-binding oligomerization domain containing 1	107607	1.503754	0.000728	0.016624



Profiles of differentially expressed genes in  $\beta$ 2AR-KO transgenic AD model annotated to be related to MHC protein complex in Gene Ontology (Part II).

**Table 3b**

Items	Gene ID	Fold Chg.	p Value	q Value
Cyclin D1	12443	1.489153	0.000724	0.016556
DnaJ (Hsp40) homolog, subfamily C, member 18	76594	1.461304	0.000678	0.015844
CD3 antigen, epsilon polypeptide	12501	1.42577	0.003388	0.04123
Fc receptor, IgG, low affinity III	14131	1.411944	0.001029	0.021051
Fc receptor, IgG, alpha chain transporter	14132	1.33175	0.003783	0.044161
ATP-binding cassette, sub-family B (MDR/TAP), member 9	56325	1.305657	0.001726	0.028518
Wolfram syndrome 1 homolog (human)	22393	1.289007	0.003984	0.045336
SEC63-like ( <i>S. cerevisiae</i> )	140740	1.193609	0.001819	0.029331
HERPUD family member 2	80517	-1.22882	0.003121	0.039352
Heat shock protein 90, alpha (cytosolic), class A member 1	15519	-1.23512	0.001109	0.021868
Heat shock 105kDa/110kDa protein 1	15505	-1.24793	0.001371	0.024635
DnaJ (Hsp40) homolog, subfamily B, member 11	67838	-1.29418	0.000546	0.014039
Chaperonin containing Tcp1, subunit 3 (gamma)	12462	-1.35609	0.000138	0.006112
Heat shock protein 90 alpha (cytosolic), class B member 1	15516	-1.4133	0.000366	0.011053
Heat shock protein 90, beta (Grp94), member 1	22027	-1.41384	0.002119	0.031692
T-complex protein 1	21454	-1.41447	0.002478	0.034708
Heat shock protein 5	14828	-1.43609	0.001112	0.021872
DnaJ (Hsp40) homolog, subfamily A, member 4	58233	-1.46868	5.87E-05	0.00359
DnaJ (Hsp40) homolog, subfamily C, member 3	100037258	-1.50583	0.000205	0.007744
Serine/arginine-rich splicing factor 10	14105	-1.54974	0.002451	0.034597
Heat shock protein 1 (chaperonin)	15510	-1.76402	0.000238	0.008435
Heat shock protein 8	15481	-1.8216	0.000412	0.011816
Calreticulin	12317	-1.86027	0.001086	0.021609
p53 and DNA damage regulated 1	68559	-15.3898	1.55E-12	5.96E-09
Nucleotide-binding oligomerization domain containing 1	107607	1.503754	0.000728	0.016624

Profiles of differentially expressed genes in  $\beta$ 2AR-KO transgenic AD model annotated to be related to hydrolase activity in Gene Ontology (Top 30 increase).

**Table 4a:**

Items	Gene ID	Fold Chg.	p Value	q Value
Cathepsin C	13032	5.514072	0.002342	0.033643
Kallikrein related-peptidase 6	19144	5.377842	2.08E-07	9.51E-05
Cathepsin E	13034	5.167045	2.08E-07	9.51E-05
Proteasome (prosome, macropain) subunit, beta type 9 (large multifunctional peptidase 2)	16912	2.908455	3.20E-05	0.00244
Plasminogen activator, urokinase	18792	2.825956	1.57E-09	2.64E-06
Lysozyme 1	17110	2.51725	1.58E-06	0.000345
Chymotrypsin-like elastase family, member 1	109901	2.386791	1.55E-08	1.38E-05
Ectonucleotide pyrophosphatase/phosphodiesterase 6	320981	2.239908	1.35E-07	7.72E-05
CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) phosphatase, subunit 1	67655	2.216111	6.35E-06	0.000841
Peptidyl arginine deiminase, type II	18600	2.204623	9.15E-06	0.001061
Heparanase	15442	2.188486	6.48E-07	0.000198
Dual specificity phosphatase 1	19252	2.12332	0.002496	0.034772
Caspase 1	12362	2.095731	6.53E-05	0.00386
Phosphatidic acid phosphatase type 2C	50784	2.080684	1.81E-07	9.01E-05
Ribonuclease, RNase A family 4	58809	2.073185	2.71E-07	0.000106
Phospholipase D family, member 4	104759	2.053021	1.40E-06	0.000322
Lysozyme 2	17105	2.031321	6.58E-06	0.000859
Agmatine ureohydrolase (agmatinase)	75986	2.030783	0.000198	0.007654
ATP-binding cassette, sub-family B (MDR/TAP), member 1B	18669	2.025545	3.16E-05	0.002415
Cathepsin Z	64138	2.001336	0.000111	0.0053
Prolylcarboxypeptidase (angiotensinase C)	72461	1.972664	5.00E-05	0.003226
N-sulfoglucosamine sulfohydrolase (sulfamidase)	27029	1.965037	1.81E-05	0.001656
glucuronidase, beta	110006	1.954243	1.93E-05	0.001715
Suppression of tumorigenicity 14 (colon carcinoma)	19143	1.915971	0.000214	0.007947
Proprotein convertase subtilisin/kexin type 4	18551	1.914996	0.000861	0.0187
2',3'-cyclic nucleotide 3' phosphodiesterase	12799	1.91379	8.14E-06	0.000968

Items	Gene ID	Fold Chg.	p Value	q Value
Proteasome (prosome, macropain) subunit, beta type 8 (large multifunctional peptidase 7)	16913	1.861686	0.000539	0.013966
paraoxonase 3	269823	1.86039	1.43E-05	0.001416
Phospholipase C, gamma 2	234779	1.819061	9.23E-06	0.001066
Mannosidase 2, alpha B1	17159	1.755669	6.14E-05	0.003691

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Profiles of differentially expressed genes in  $\beta$ 2AR-KO transgenic AD model annotated to be related to hydrolase activity in Gene Ontology (Top 30 decrease).

**Table 4b:**

Items	Gene ID	Fold Chg.	p Value	q Value
DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked	26900	-2.10674	0.002199	0.032358
Phosphodiesterase 4A, cAMP specific	18577	-1.98027	7.42E-05	0.004177
Protein tyrosine phosphatase, receptor type, O	19277	-1.97666	0.00269	0.035996
Proteasome (prosome, macropain) subunit, beta type 5	19173	-1.96916	1.71E-05	0.001616
Glucosamine-6-phosphate deaminase 1	26384	-1.95682	4.02E-05	0.0028
N-acyl phosphatidylethanolamine phospholipase D	242864	-1.93054	0.000285	0.009404
acyl-CoA thioesterase 1	26897	-1.86093	0.000536	0.013913
Spastin	50850	-1.75118	9.36E-06	0.001069
DIS3 mitotic control homolog (S. cerevisiae)	72662	-1.74871	0.000286	0.009435
Ectonucleoside triphosphate diphosphohydrolase 6	12497	-1.74754	5.98E-05	0.003631
Rhomboid, veinlet-like 3 (Drosophila)	246104	-1.7434	2.35E-05	0.001954
Acyl-CoA thioesterase 7	70025	-1.73511	4.17E-05	0.002877
DEAD (Asp-Glu-Ala-Asp) box polypeptide 5	13207	-1.70454	0.000419	0.011946
Spastin	50850	-1.7034	0.001148	0.022269
Protease, serine, 53	330657	-1.69693	0.001317	0.024066
Esterase D/formylglutathione hydrolase	13885	-1.6703	1.03E-05	0.001143
Mannan-binding lectin serine peptidase 2	17175	-1.65176	0.00124	0.023313
Haloacid dehalogenase-like hydrolase domain containing 2	76987	-1.64692	9.52E-05	0.004837
Bisphosphate 3'-nucleotidase 1	23827	-1.64313	0.000246	0.008591
OTU domain, ubiquitin aldehyde binding 2	68149	-1.63286	0.000229	0.008222
Endo/exonuclease (5'-3'), endonuclease G-like	208194	-1.58646	0.001819	0.029331
Histocompatibility 13	14950	-1.57331	0.000107	0.005193
Iduronate 2-sulfatase	15931	-1.573	0.00208	0.031336
YME1-like 1 (S. cerevisiae)	27377	-1.57208	0.000551	0.014096
Adenosine deaminase-like	75894	-1.57155	0.002845	0.037159
Angiogenin, ribonuclease, RNase A family, 5	11727	-1.5621	0.000464	0.012644

Items	Gene ID	Fold Chg.	p Value	q Value
Inositol polyphosphate-4-phosphatase, type II	234515	-1.54742	0.004207	0.046872
Expressed sequence AI464131	329828	-1.54346	0.000783	0.017454
Myotubularin related protein 2	77116	-1.5103	0.003353	0.041002
Alkaline ceramidase 2	230379	-1.50696	8.64E-05	0.004576

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Profiles of differentially expressed genes in  $\beta$ 2AR-KO transgenic AD model annotated to be related to unfolded protein binding in Gene Ontology.

**Table 5:**

Items	Gene ID	Fold Chg.	p Value	q Value
Eukaryotic translation initiation factor 2-alpha kinase 2	19106	2.220892	4.71E-07	0.00016
DnaJ (Hsp40) homolog, subfamily C, member 16	214063	1.713747	1.49E-05	0.001453
Cyclin D1	12443	1.489153	0.000724	0.016556
DnaJ (Hsp40) homolog, subfamily C, member 18	76594	1.461304	0.000678	0.015844
Wolfram syndrome 1 homolog (human)	22393	1.289007	0.003984	0.045336
SEC63-like ( <i>S. cerevisiae</i> )	140740	1.193609	0.001819	0.029331
HERPUD family member 2	80517	-1.22882	0.003121	0.039352
Heat shock protein 90, alpha (cytosolic), Class A member 1	15519	-1.23512	0.001109	0.021868
Heat shock 105kDa/110kDa protein 1	15505	-1.24793	0.001371	0.024635
DnaJ (Hsp40) homolog, subfamily B, member 11	67838	-1.29418	0.000546	0.014039
Chaperonin containing Tcp1, subunit 3 (gamma)	12462	-1.35609	0.000138	0.006112
Heat shock protein 90 alpha (cytosolic), class B	15516	-1.4133	0.000366	0.011053
Heat shock protein 90, beta (Grp94), member 1	22027	-1.41384	0.002119	0.031692
T-complex protein 1	21454	-1.41447	0.002478	0.034708
Heat shock protein 5	14828	-1.43609	0.001112	0.021872
DnaJ (Hsp40) homolog, subfamily A, member 4	58233	-1.46868	5.87E-05	0.00359
DnaJ (Hsp40) homolog, subfamily C, member 3	100037258	-1.50583	0.000205	0.007744
Serine/arginine-rich splicing factor 10	14105	-1.54974	0.002451	0.034597
Heat shock protein 1 (chaperonin)	15510	-1.76402	0.000238	0.008435
Heat shock protein 8	15481	-1.8216	0.000412	0.011816
Calreticulin	12317	-1.86027	0.001086	0.021609
p53 and DNA damage regulated 1	68559	-15.3898	1.55E-12	5.96E-09

Profiles of differentially expressed genes in  $\beta$ 2AR-KO transgenic AD model annotated to be related to Alzheimer's disease in KEGG's pathways.

**Table 6:**

Items	Gene ID	Fold Chg.	p Value	q Value
Cytochrome c oxidase, subunit VI a, polypeptide 2	12862	2.523729	1.44E-05	0.001417
ATPase, Ca++ transporting, cardiac muscle, fast twitch 1	11937	1.512032	0.000439	0.012244
Beta-site APP-cleaving enzyme 2	56175	1.506286	8.44E-05	0.004494
Inositol 1,4,5-triphosphate receptor 2	16439	1.451202	0.000228	0.008213
Lipoprotein lipase	16956	1.413552	0.000202	0.007714
Apolipoprotein E	11816	1.35843	0.000376	0.01129
Caspase 8	12370	1.336963	0.003373	0.041103
Calpain 1	12333	1.311871	0.001259	0.023432
NADH dehydrogenase (ubiquinone) flavoprotein 3	78330	1.231451	0.004652	0.049888
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit B1	11950	-1.26575	0.004255	0.047107
Guanine nucleotide binding protein, alpha q polypeptide	14682	-1.26842	0.003271	0.040466
Phospholipase C, beta 4	18798	-1.29642	0.000965	0.020124
Anterior pharynx defective 1c homolog (C.elegans)	68318	-1.56577	0.000409	0.011797
RIKEN cDNA 1500003O03 gene	56398	-1.58374	2.07E-05	0.001806
Cytochrome c oxidase subunit VIIa polypeptide 2-like	20463	-10.3201	8.36E-14	1.12E-09